Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Presentation CCVVC 2016

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Presenter: Marc P. Bonaca

June 15, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.